Neurocrine Biosciences
NBIX
437 hedge funds and large institutions have $8.45B invested in Neurocrine Biosciences in 2022 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 157 increasing their positions, 158 reducing their positions, and 43 closing their positions.
203% more call options, than puts
Call options by funds: $111M | Put options by funds: $36.6M
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
44% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 43
3% more funds holding
Funds holding: 426 → 437 (+11)
1% more capital invested
Capital invested by funds: $8.35B → $8.45B (+$99.3M)
1% less repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 158
1.04% less ownership
Funds ownership: 94.86% → 93.82% (-1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$63.9M |
| 2 |
AC
Armistice Capital
New York
|
+$62.2M |
| 3 |
DM
Deerfield Management
New York
|
+$32.8M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$32.3M |
| 5 |
BlackRock
New York
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$101M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$63.5M |
| 3 |
Two Sigma Investments
New York
|
-$31.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.7M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28.1M |
NBIX Hedge Fund Activity: Q2 2022 in Review
437 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2022, worth a combined $8.45B — up 1.2% from $8.35B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new NBIX positions and 43 closed out — a net gain of 19 holders — while 157 added to existing stakes and 158 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $63.9M. The largest seller was Janus Henderson Group, cutting an estimated $101M.
- 437 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2022, up from 426 in Q1 2022.
- Funds reported $8.45B of Neurocrine Biosciences stock for Q2 2022, up 1.2% quarter-over-quarter.
- 62 funds opened new Neurocrine Biosciences positions in Q2 2022 and 43 closed out, a net change of +19 holders.
- The largest Neurocrine Biosciences buyer in Q2 2022 was Holocene Advisors, an estimated $63.9M added.
- The largest Neurocrine Biosciences seller in Q2 2022 was Janus Henderson Group, an estimated $101M sold.
Based on aggregated 13F filings for Q2 2022.